| Theme | An up-to-date review of the molecular-targeted therapies for inflammatory bowel disease | |
|---|---|---|
| Title | Vaccination for patients with inflammatory bowel disease treated with biologics and small-molecule immunosuppressives | |
| Publish Date | 2021/09 | |
| Author | Katsuya Endo | Division of Gastroenterology, Tohoku Medical and Pharmaceutical University School of Medicine |
| Author | Tomonori Satoh | Division of Gastroenterology, Tohoku Medical and Pharmaceutical University School of Medicine |
| Author | Yoko Kawakami | Division of Gastroenterology, Tohoku Medical and Pharmaceutical University School of Medicine |
| Author | Yuki Yoshino | Division of Gastroenterology, Tohoku Medical and Pharmaceutical University School of Medicine |
| Author | Yoshiteru Sasaki | Division of Gastroenterology, Tohoku Medical and Pharmaceutical University School of Medicine |
| Author | Tomofumi Katayama | Division of Gastroenterology, Tohoku Medical and Pharmaceutical University School of Medicine |
| [ Summary ] | It is essential to confirm the history of infection, vaccination, and serum levels of anti-virus antibodies before treatment with biologics and small-molecule immunosuppressives for patients with inflammatory bowel disease (IBD). Live vaccines against measles, rubella, mumps, and varicella are contraindicated during immunosuppressive treatment, whereas live vaccination before starting immunosuppressants does not have an impact. However, inactivated vaccines, such as influenza and pneumococcal vaccines, can be administered even during immunosuppressive treatment. Nevertheless, it should be noted that antibody production may decrease during immunosuppressive treatment. With regard to COVID-19, SARS-CoV-2 vaccination is recommended for patients with IBD, though its efficacy during immunosuppressive treatment for IBD needs to be clarified. | |